Category: Market Commentary

Leap Therapeutics, Inc. (LPTX) saw a decrease of 8.21% after LPTX Announces the Proposed Public Offering of Common Stock and Pre-Funded Warrants. However, the last trading session closed at $3.41 with an increase of 23.1%. Proposed Public Offering of Common Stock and Pre-Funded Warrants LPTX announced on 1st September 2021 that Leap has started an underwritten public offering of its common stock. The company plans to issue and sell pre-funded warrants to buy shares of its common stock to specified investors. Moreover, Leap will sell all of the common stock and warrants in the offering. Leap wants to provide the

Sesen Bio, Inc. (SESN), a late-stage clinical company, has seen an increase of 0.83% in the premarket trading session. As a consequence, SESN stock is changing hands at $0.84 at the time of this writing. There appears to be no obvious reason for this increase, i.e. SEC filing or press release. On Monday, SESN stock closed the day at $0.83 after declining 8.29% in the regular trading session. Let’s have a discussion about some recent developments of SESN stock. SESN approved retention program On the 9th of September, SESN Board of Directors and compensation committee approved a retention program. The

2Verastem Inc (VSTM) has seen an increase of 25.72% in the premarket after the company announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766. Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 VSTM presented a brief oral presentation summarising new results from the current Phase 1/2 FRAME research on 19th September 2021. The FRAME trial is looking at VS-6766, a Verastem RAF/MEK inhibitor, in conjunction with defactinib. A Verastem FAK inhibitor is the one in which patients with low-grade serous ovarian cancer (LGSOC). The results will be presented at the European Society of Medical Oncology (ESMO) Congress 2021.

TRACON Pharmaceuticals, Inc. (TCON) undergoes an increase of 6.58% in the premarket today. However, the last trading session concluded at $3.80 with a decrease of 0.26%. Second Quarter 2021 Financial Results TCON reported second-quarter 2021 financial results on 12th August 2021. At the end of June 2021, cash totaled $25.6 million, down from $36.1 million at the end of December 2020. The second quarter of 2021 saw $3.1 million in research and development costs, up from $2.2 million in the second quarter of 2020. The second quarter of 2021 saw $6.1 million in general and administrative costs, up from $2.1

Rekor Systems, Inc. (REKR) stock has increased to 9.8% in the aftermarket. However, the last trading session closed at $9.69 with a gain of 0.21%. What’s happening with the stock? Let’s study more about REKR and analyze all the recent news launched by the company. REKR Announced Selection of Waycare Technologies REKR selected Waycare Technologies on 9th September 2021. The Louisiana Department of Transportation and Development (LaDOTD) has chosen its Waycare Technologies subsidiary for a pilot program. This will help reduce congestion and collisions in the Baton Rouge area. Also, it will promote speed harmonization for a safer driving experience.

Shares of the Helbiz, Inc. (HLBZ) stock skyrocketed today following the announcement of a partnership between Helbiz Media and Fox Networks Group. HLBZ stock price saw a surge of 172.50% to reach $24.52 a share at the time of this writing. The trading volume as of now was 15,651,424, far higher as compared to the average trading volume. Let’s discuss more about this stock. Helbiz, Inc operates by providing micro-mobility services across the globe. Its convenient platforms operating in 35 cities worldwide contain a fleet of vehicles including e-mopeds, e-bicycles, and e-scooters. It is also focusing on the expansion of

Luokung Technology Corp. (LKCO) has experienced an increase of 3.27% in the premarket after signing a cooperation agreement with Microsoft. However, the last trading session closed at $1.5 with an incline of 11.94%. LKCO Announces eMapgo Signs Cooperation Agreement with Microsoft LKCO reported on 16th September 2021 that it has linked a collaboration deal with Microsoft to offer autonomous driving services for manufacturers. EMG will collaborate with Microsoft to provide automakers with services such as data collecting, storage, and analysis. This will help automakers, deploy autonomous driving technology more quickly in China. EMG and Microsoft want to leverage their respective

Lion Group Holding Ltd. (LGHL) has experienced an incline of 5.26% in the aftermarket. However, the last trading session closed at $1.14 with a decrease of 6.56%. Strategic Partnership with Dawa Future Graphic Technology LGHL announced its strategic merger with Dawa Future Graphic Technology on 17th August 2021. The two businesses will collaborate to create and develop the Metaverse AI tool – “Cloud Production Platform”. This will develop a new type of digital market and establish a leadership position in the Metaverse field’s construction and growth. Moreover, Dawa Technology brings together seasoned researchers, developers, artists, and project operation teams to

Tuesday Morning Corporation (TUEM) experienced an incline of 11.56% in the aftermarket. However, the last trading session concluded at $1.73 with an increase of 2.98%. What’s happening? TUEM has not released any latest news on today’s date. But let’s have a look at the recent news. TUEM announced Fiscal Results 2021 TUEM reported its fourth-quarter and full-year fiscal 2021 results on 9th September 2021. Marc Katz has been the Principal and Chief Operating Officer, Jennifer Robinson as Chief Financial Officer, and Bill Baumann as Chief Information Officer, according to the company. Firstly, in the fiscal year 2019, net sales were

Sonnet Biotherapeutics Holdings Inc. (SONN) stock prices were down by 7.67% as of the market closing on September 14th, 2021. This brought the price per share down to USD$0.56 at the end of the trading day. Subsequent premarket fluctuations have seen the stock surge by 25.40%, bringing it up to USD$0.71. SONN Stock’s New Candidate August 30th, 2021 saw SONN stock announce the selection of a novel development candidate after the completion of comparative studies in a mouse melanoma model. The selected candidate will be the company’s second bispecific compound to integrate IL-12 with the company’s Fully Human Albumin Binding